Search clinical trials for: Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir

Total 2152 results

AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis (TURQUOISE-II)

Compensated Cirrhosis | Chronic Hepatitis C Infection
AbbVie

Completed

Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults

Chronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
Assiut University
Sohag University; South Valley University

Completed

Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure

HCV Coinfection

Egypt
AbbVie

Completed

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

Chronic Hepatitis C | Hepatitis C Virus | Compensated Cirrhosis
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV) (Navigator)

Hepatitis C Virus
University of Florida
Patient-Centered Outcomes Research Institute; Merck Sharp & Dohme LLC; AbbVie

Completed

Study of Oral Treatments for Hepatitis C (PRIORITIZE)

Chronic Hepatitis C

United States
AbbVie

Completed

An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine

Chronic Hepatitis C | Chronic Hepatitis C Infection
Assiut University

Unknown

Effect Of DAAs For Treatment Of HCV On Normal Kidney

Antiviral Drug Adverse Reaction
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults (MALACHITE II)

Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

Chronic Hepatitis C Infection

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection

Chronic Hepatitis C Infection
Humanity and Health Research Centre
Beijing 302 Hospital; Nanfang Hospital of Southern Medical University

Completed

DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) (DASCO)

Chronic Hepatitis C Infection | Hepatitis B Reactivation | HBV Coinfection

China
AbbVie

Completed

Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection (GIFT I)

Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

Chronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)

United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
Parc de Salut Mar

Completed

Impact of Antiviral Therapy on Gastroesophageal Varices.

Cirrhosis | Chronic Hepatitis C
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection (Quartz II/III)

Chronic Hepatitis C Virus Infection
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before (MALACHITE 1)

Chronic Hepatitis C Infection
AbbVie

Completed

Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection (GIFT-II)

Hepatitis C Virus
Pfizer

Completed

A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System

COVID-19

Spain, United States, Australia, Canada, Bulgaria, Slovakia, Mexico, Hungary, Brazil
AbbVie

Completed

Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1

HCV Infection

United States
Abbott

Completed

Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

HCV Infection

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection (PEARL-I)

Hepatitis C, Chronic
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Chronic Hepatitis C Virus Infection

United States, Puerto Rico
National Taiwan University Hospital

Completed

eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

Hepatitis C | Viral Hepatitis C | Renal Disease

Taiwan
Beni-Suef University

Completed

Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4

Hepatitis C Virus Infection
AbbVie (prior sponsor, Abbott)

Completed

Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Chronic Hepatitis C | Hepatitis C Virus (HCV) Infection

United States, Puerto Rico
First Affiliated Hospital of Zhejiang University
Ascletis Pharmaceuticals Co., Ltd.

Completed

Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects (RTV)

Healthy Volunteer

China
Pfizer

Completed

A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection

COVID-19

United States, Russian Federation, Thailand, Czechia, Colombia, Bulgaria, Japan, South Africa, Turkey, Argentina, Hungary, Malaysia, Mexico, Poland, Spain, Ukraine, Brazil
Tanta University

Completed

Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection

Hepatitis C

Egypt
Beni-Suef University

Completed

Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients

Chronic Hepatitis C Virus Infection

Egypt
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study

Chronic Hepatitis C
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Hepatitis C | Hepatitis C Virus | Chronic Hepatitis C Infection

United States
AbbVie

Completed

A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

Chronic Hepatitis C | Hepatitis C Virus
Karolinska Institutet
Karolinska University Hospital; Pfizer

Recruiting

imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC)

COVID-19 | Post-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | POTS - Postural Orthostatic Tachycardia Syndrome | Postinfectious Inflammation | Postinfectious Disorder

Sweden
Menoufia University

Completed

Omega-3 Fatty Acid for Critically Ill Patients.

Sepsis
Pfizer

Completed

A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

COVID-19

United States, Taiwan, Italy, Canada, Greece
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

To Evaluate SSD8432/Ritonavir in Adults With COVID-19

COVID-19
Ahn-Gook Pharmaceuticals Co.,Ltd
Samsung Medical Center; Seoul St. Mary's Hospital; Seoul National University... and other collaborators

Completed

Clinical Trial to Evaluate the Safety and Efficacy of AGR Tablet as a Treatment of Perennial Allergic Rhinitis in Korean

Allergic Rhinitis | Perennial Allergic Rhinitis | Non-seasonal Allergic Rhinitis

Korea, Republic of
Shanghai Mental Health Center

Unknown

The Influence of Omega-3 Fatty Acid on the Violence of Schizophrenia Patient and the Possible Mechanism

Schizophrenia

China
University College, London
LifeArc

Completed

FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals (FLARE)

COVID-19

United Kingdom
Rambam Health Care Campus

Completed

Green Tea Effect on Anthropometric, Oxidation and Inflammation Parameters in Physically Active vs. Sedentary Elders (GT)

Aging

Israel
AstraZeneca

Completed

SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.

Healthy Elderly | Mild-Moderate Alzheimer's Disease

United States
AbbVie (prior sponsor, Abbott)

Completed

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 (Champion2)

Hepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1

United States, Puerto Rico
The HIV Netherlands Australia Thailand Research...
Ministry of Education, Thailand

Completed

Efficacy and Safety of Single Versus Double Ritonavir-boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens

HIV Infections | HIV Infection

Thailand
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical Study

COVID-19
Brigham and Women's Hospital
National Heart, Lung, and Blood Institute (NHLBI); GlaxoSmithKline

Completed

Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging (OmegaREMODEL)

Myocardial Infarction | Death, Sudden, Cardiac

United States
Bio Genuine (Shanghai) Biotech Co., Ltd.

Recruiting

Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids.

Uterine Fibroids | Heavy Menstrual Bleeding

China
GlaxoSmithKline

Completed

A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

HIV Infections | Infection, Human Immunodeficiency Virus

United States
Haukeland University Hospital
University of Oslo; Oslo University Hospital; University of Bergen; Norwegian University... and other collaborators

Recruiting

PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway (PanoramicNOR)

COVID-19 | SARS-CoV2 Infection | Post COVID-19 Condition, Unspecified

Norway
Gilead Sciences

Active, not recruiting

Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B

Chronic Hepatitis B

Taiwan, New Zealand

3

Subscribe